Source: http://www.google.es/patents/US8951555
Timestamp: 2018-01-18 04:18:45
Document Index: 389389351

Matched Legal Cases: ['application No. 01992565', 'application No. 10', 'Application No. 2001', 'Application No. 2006', 'Application No. 10177508', 'Application No. 10180945', 'art 1', 'application No. 2013', 'Application No. 01', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 05019453', 'Application No. 01992565', 'Application No. 10177508', 'Application No. 10179086', 'Application No. 10179087', 'Application No. 10180984', 'Application No. 10181032']

Patente US8951555 - Controlled release hydrocodone formulations - Google Patentes
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material....http://www.google.es/patents/US8951555?utm_source=gb-gplus-sharePatente US8951555 - Controlled release hydrocodone formulations
Número de publicación US8951555 B1
Número de solicitud US 14/520,032
También publicado como CA2427815A1, CA2427815C, CN1479614A, CN100518827C, CN101317825A, CN101653411A, CN103690540A, EP1337244A1, EP1337244A4, EP2263658A1, EP2283829A1, EP2295042A1, EP2932964A1, US6733783, US7514100, US8142811, US8231898, US8361499, US8551520, US8647667, US8715721, US9023401, US9056052, US9060940, US9198863, US9205055, US9205056, US9289391, US9504681, US9517236, US9526724, US9572804, US9572805, US9669023, US9682077, US20020192277, US20040047907, US20090202629, US20110038927, US20120263788, US20130158061, US20130295177, US20130302418, US20140199394, US20150037409, US20150110870, US20150148367, US20150238418, US20150258089, US20150258090, US20150265537, US20160151288, US20160151292, US20160151361, US20160158223, US20160158224, US20170087151, US20170087152, US20170151229, WO2002036099A1
Número de publicación 14520032, 520032, US 8951555 B1, US 8951555B1, US-B1-8951555, US8951555 B1, US8951555B1
Citas de patentes (470), Otras citas (176), Citada por (17), Clasificaciones (29)
US 8951555 B1
15 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 12/982,386 on Apr. 18, 2013.
16 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 13/833,263 on May 12, 2014.
17 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 13/833,263 on Nov. 3, 2014.
18 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/094,968 on May 9, 2014.
19 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/094,968 on Nov. 5, 2014.
20 Applicant-Initiated Interview Summary issued in connection with U.S. Appl. No. 14/483,395 on Oct. 3, 2014.
21 Approval Package for NDA 20-616/5-001 (Kadian®), 1997.
22 Benziger, et al., "A Pharmacokinetic/Pharmacodynamic Study of Controlled-Release Oxycodone", 1997.
23 Brendenberg "New Concepts in Administration of Drugs in Tablet Form: Formulation and Evaluation of a Sublingual Tablet for Rapid Absorption and Presentation of an Individualized Dose Administration System Acta Universitiatis Upsaliensis." Comprehensive Summaries of Uppsa/a Dissertations from the Faculty of Pharmacy 287 83 pp. Uppsala ISBN 91-554-5600-6 (2003).
24 Broomhead, et al., "Kadian™/Kapanol™—A Once Daily Mophine Formulation," European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S182 Abs 873, European Conference on Clinical Onclology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
25 Castensen et al., "USP Dissolution IV:Comparison of Methods," J. Pham. Sci 1978, 67(9), pp. 1303-1307.
26 Certain Patients Diary Cards, Drug Disposition Records, Case Reports Forms and listing which apparently correlates patient randomization number with the treatment of dosing regimen assigned to each patient, 2003.
27 Cherry DA, et al., "A comparison of Kapanol™ (a new sustained release morphine formulation), MST Continus™ and morphine solution in cancer patients: Morphine metabolite profiles and renal function," (Abstract 999) International Association for the Study of Pain, 7th World Congress on Pain, Paris Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
28 Cherry DA, et al., "Once a Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles," European Journal of Cancer; Part A General Topics 1995; 31 (S5) Suppl:S184 Abs 884, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
29 Claims pending in U.S. Appl. No. 12/982,386 on May 7, 2014.
31 Claims Pending in U.S. Appl. No. 12/982,386 on Oct. 20, 2014.
32 Claims pending in U.S. Appl. No. 13/833,263 on May 7, 2014.
33 Claims pending in U.S. Appl. No. 13/833,263 on Nov. 17, 2014.
34 Claims Pending in U.S. Appl. No. 13/833,263 on Oct. 20, 2014.
35 Claims pending in U.S. Appl. No. 14/094,968 on May 7, 2014.
36 Claims pending in U.S. Appl. No. 14/094,968 on Nov. 17, 2014.
37 Claims Pending in U.S. Appl. No. 14/094,968 on Oct. 20, 2014.
38 Claims pending in U.S. Appl. No. 14/483,395 on Nov. 17, 2014.
39 Claims Pending in U.S. Appl. No. 14/483,395 on Oct. 20, 2014.
40 Clin. Neuropharmacol Jan.-Feb. 1999; 22 (1):33-9).
41 Clin. Phannacokinet Sep. 1998; 35(3):173-90.
42 Conte. et al., Drug Del.. Ind. Pharm. (1989) 15:2583-2596.
43 D.L. Munday, et al., "Changes in Drug Release Rate 2. Effect of Temperature and Relative Humidity on Polymeric Film Coatings," 5th Cong. Int. Tech. Pharm., 1989, vol. 2, pp. 55-60.
44 Database Medline [Online] US National Library of Medicine (NLM), Bethesda, MD, US; Aug. 1994, Yasuhara H: "Ethnic factors in evaluation of drug efficacy and safety," XP002350633 Database accession No. NLM7927070.
45 Decision to refuse a European Patent application issued in connection with European patent application No. 01992565.0-1464 on Jun. 27, 2014.
46 Decision to refuse a European Patent application issued in connection with European patent application No. 10 180 984.6-1464 on Jul. 9, 2014.
47 Document CA/PL 17/07; "Misuse of Divisional Applications," by the EPO President, addressed to the EPO Committee of Patent Law. Presented at the EPO Administrative Council, dated Oct. 5, 2007.
48 Document CA/PL 3/08, presented by epi and other Professional Representatives, addressed to the EPO Committee of Patent Law. Presented at the EPO Administrative Council, dated Feb. 14, 2008.
49 Drugs Jan. 1999; 57(1 ):93-9.
50 E.Beubler, "Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken," Therapiewoche Osterreich, 7,2 (1992), pp. 1-15, English translation.
51 Emami, J. et al, "In vitro-In vivo Correlation: From Theory to Applications", J. Pharm Pharmaceut Sci, (www.cspsCanada.org) 9 (2), 169-189, 2006.
52 Encarta World English Dictionary [North American Edition] 2006 Microsoft Incorporation "Matrix", p. 1, definition 2, http://encarta.msn.com/encnet/features/dictionary/DictionaryResults.aspx?- refid=1861678516 retrieved on Apr. 30, 2006.
53 Encyclopedia of Controlled Drug Delivery, vol. 1, "In vitro-in vivo correlation," pp. 425-435 (1999).
54 Encyclopedia of Controlled Drug Delivery, vol. 2, "Oral drug delivery, small intestine & colon," pp. 698-728 (1999).
55 English Abstract of JP-08157392-A, Jun. 18, 1996.
56 English translation of Office Action issued by Japanese Patent Office in connection with corresponding Japanese Patent Application No. 2001-534353 on May 25, 2010.
57 English Translation of the Office Action issued on Mar. 22, 2011 in connection with Japanese Patent Application No. 2006-3165067.
58 EPI Journal Feb. 2007, pp. 59-60; David Harrison; "Divisional Application a continuing problem" (2007).
59 Eur. J. Pharm. Sci. Jul. 1999; 8(3):157-9.
60 European Search Report issued in connection with European Application No. 10177508.8-2123 on Sep. 11, 2010.
61 European Search Report issued on Nov. 9, 2010 in connection with European Application No. 10180945.7-2123.
62 FDA Response to a Citizen Petition, Oct. 25, 2013.
63 Flanders, P., et al., "The Control of Drug Release From Conventional Melt Granulation Matrices," Drug Development and Industrial Pharmacy, vol. 13, No. 6, pp. 1001-1022 (1987).
64 Frohof-Hulsmann et al., "Aqueous Ethyl Cellulose Dispersion Containing Plasticizers of Different Water Solubility and Hydroxypropyl Methyl-Cellulose as Coating Material for Diffusion Pellets II: Properties of Sprayed Films", European Journ. of Pharma and Biopharma., vol. 48, pp. 67-75, 1999.
65 Geoffrey K. Gourlay, et al.,"The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions," Journal of Pain and Symtoms Management, vol. 6., No. 7, Oct. 1991, pp. 431-436.
66 Giunchedi et al., J. Pharm. (1991) 77:177-181.
67 Goodman and Gilman's, The Pharmacological Basis of Therapeutics, pp. 7-8 (1990).
68 Gourlay et al., "Proceedings of the 7th World Congress on Pain; A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus, and Morphine Solution in Cancer Patients," Pharmacolinetic Aspects of Morphine and Morphine Metabolites Progress in Pain Research and Management vol. 2 pp. 631-643, 1993.
69 Gourlay GK, et al., "A comparison of Kapanol™ (A new sustained release morphine formulation), MST Contius® and morphine solution in cancer patients: pharmacokinetics aspects," (Abstract 998) International Association for the Study of Pain, 7th World Congress on Pain Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
70 Gourlay, et al., "Influence of a High-Fat Metal on the Absorption of Morphine From Oral Solutions," Clin. Pharmacol. Ther., vol. 46, Oct. 1989, pp. 463-468.
71 Gourlay, et al., "Once a Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, In the Treatment of Cancer Pain: Pharmacokinetic Aspects," European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S187 Abs 897, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995.
72 Guidance for Industry, "Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/ In vivo Correlation" (FDA, 1997).
73 Guidance for Industry, Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/ In Vivo Correlations; US Dept. of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research (CDER), Sep. 1997, pp. 1-24.
74 Gustafsson et al., "Characterisation of Particle Properties and Compaction Behaviour of Hydroxypropyl Methylcellulose with Different Degrees of Methoxy/Hydroxypropyl Substitution", EP Journ of Pharmaceutical Sci. 9, pp. 171-184, 1999.
75 H.F. Stowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain," Anesthesia, 1985, vol. 40, pp. 438-440.
76 Hansch C et al.,"Comprehensive Medicinal Chemistry, vol. 5 Biopharmaceutics," Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds, Oxford, Pergamon Press, GB, vol. 5, 1990, pp. 251-278, XP008054499.
77 Hyppola et al.,"Evaluation of Physical Properties of Plasticized Ethyl Cellulose Films Cast From Ethanol Solution Part 1", International Journ. of Pharma., vol. 133, pp. 161-170, 1996.
78 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/025914 dated Aug. 28, 2012.
79 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035767 dated Nov. 13, 2012.
80 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035768 dated Nov. 13, 2012.
81 International Preliminary Report on Patentability and Written Opinion re: PCT/US2011/035770 dated Nov. 13, 2012.
82 International Search Report and Written Opinion for PCT/US2007/020041, dated Feb. 25, 2008.
83 Investigator agreements between the study organizers and certain of the principal investigators, 2003.
84 J. Control Release Aug. 5, 1999; 60(2-3):391-7.
85 J. Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation," Pain and Symptom Manag., vol. 4 (3), pp. 146-151,1989.
86 J. Lapin et al., "Guidelines for Use of Controlled Release Oral Morphine in Cancer Pain Management," Cancer Nursing, vol. 12 (4), pp. 202-208, (1989).
87 J. Pharm. Pharmacol Dec. 1996; 48(12):1276-84.
88 J. Pharm. Sci. Feb. 1993; 82(2):113-26.
89 Johnson, Sarah J., "Opioid Safety in Patients With Renal or Hepatic Dysfunction" Pain Treatment Topics pp. 1-9 (Release date Jun. 2007; updated Nov. 30, 2007).
90 Kadian® Prescribing Information 2006.
91 Kaiko et al., "A Single-Dose Study of the Effect of Food Ingestion and Timing of Dose Administration on the Pharmacokinetic Profile of 30-mg Sustained-Release Morphine Sulfate Tablets," Current Terapeutic Research, vol. 47, No. 5, May 1990, pp. 869-878.
92 Kaiko R.F., "Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient," Anesthesiology and Pain Management 1991 pp. 193-212.
93 Lippold, B. C., Constant or Pulsed Delivery of Active Substance?, Pharmacie in uns Zeit, Jan. 13-31, 1990, No. 1.
94 M.H. Beers: "The Merck Index, 11th edition," 1989, Merck & Co. CP002606249.
95 MacCarrone C. et al.,"Single Dose Pharmacokinetics of Kapanol™ a New Oral Sustained-Release Morphine Formulation,"Clinical Drug Investigation 1994:7 (5) 262-274.
96 McTaggart, Celia M., et al., "The evaluation of formulation and processing conditions of a melt granulation process," International Journal of Pharmaceutics, vol. 19, pp. 139-148 (1984).
97 Merk Index, 13th edition, entry 4806: hydrocodone (2001).
98 MS Contin® Prescribing Information 2012.
99 MS Contin—Frequency of Daily Dosing (NDTI)—Jun. 1991-May 1992.
100 MS Contin-Frequency of Daily Dosing, Jan.-Nov. 1990.
101 MS Contin—Frequency of Daily Dosing, Jan.-Nov. 1990.
102 Office Action issued in connection with Chinese Patent Application No. CN 201210130057.4 on Oct. 11, 2014.
103 Office Action issued in connection with Japanese patent application No. 2013-168584 on Sep. 16, 2014.
104 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Apr. 10, 2012.
105 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Apr. 30, 2013.
106 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Aug. 13, 2014.
107 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Dec. 19, 2013.
108 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Dec. 27, 2012.
109 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Feb. 26, 2014.
110 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Nov. 5, 2012.
111 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Oct. 9, 2014.
112 Office Action issued in connection with U.S. Appl. No. 12/982,386 on Sep. 4, 2013.
116 Office Action issued in connection with U.S. Appl. No. 14/094,968 on Feb. 6, 2014.
117 Office Action issued in connection with U.S. Appl. No. 14/094,968 on Jun. 24, 2014.
118 Office Action issued in connection with U.S. Appl. No. 14/094,968 on Oct. 3, 2014.
119 Office Action issued in connection with U.S. Appl. No. 14/483,395 on Oct. 9, 2014.
120 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Apr. 10, 2012.
121 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Apr. 30, 2013.
122 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Aug. 13, 2014.
123 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Feb. 26, 2014.
124 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Nov. 5, 2012.
125 Office Action issued in in connection with U.S. Appl. No. 12/982,386 on Sep. 4, 2014.
126 Office Action issued on Jul. 27, 2012, in connection with European Application No. 01 992 565.0-2123.
127 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 177 508.8-2123.
128 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 179 086.3-2123.
129 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 180 945.7.
130 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 180 984.6.
131 Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 181 032.3.
132 Office Action issued on May 24, 2011, in connection with European Application No. 10 179 087.1-2123.
133 Opinion Expressed by the Board of Appeal in the Summons to Oral Proceedings in Case EP02026247 ( May 24, 2011).
134 Oxycontin® Prescribing Information 2010.
135 Patient consent forms, apparently for four study participants, 2003.
136 Physicians Desk Reference 1994, 48th Edition, pp. 1821-1824.
137 Physician's Desk Reference 57th ed. 2003 p. 1184-1185 (package insert information for ACTIQ).
138 Plummer JL, et al., "A comparison of Kapanol™ (a new sustained release morphine formulation) MST Continus™ and mophine solution in cancer patients: pharmcodynamic aspects," (Abstract 1000) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
139 Portenoy et al. "Fentanyl Buccal Tablet (FBT) for Relief of Breakthrough Pain in Opioid-Treated Patients with Chronic Low Back Pain", Current Medical Research and Opinion, vol. 23(7), pp. 223-233, 2007.
140 Portenoy et al. "Fentanyl Buccal Tablet (FBT) for Relief of Breakthrough Pain in Opioid-Treated Patients with Chronic Low Back Pain: A Randomized, Placebo-Controlled Study", ASRA 06, Final Abstract, Submitted Aug. 4. 2007.
141 R.K. Kaiko, "The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature," Medical Department, The Pudue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989).
142 R.K. Portenoy, et al., "A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacolinetics and Pharmacodynamics of Kapanol® Capsules Given Every 24 hours and Every 12 hours with MS Contin® Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain," Memorial Hospital IRB Protocol pp. 379-381, 1993.
143 Ratain M J et al., "Population Pharmacodynamic Study of Amonafide: A Cancer and Leukemia Group B Study," Journal of Clinical Oncology, Grune and Stratton, New York, NY, US, vol. 13, No. 3, Mar. 1995, pp. 741-747, XP008044974 ISSN: 0732-183X.
144 Robert F. Kaiko, et al., "Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food," The Hospice Journal, vol. 6(4) 1990, pp. 17-30.
145 S. Bloomfield, et al., "Analgesic Efficacy and Potency of Two Oral Controlled-Release Morphine Preparations Clin. Pharmacol,"Ther., vol. 53, No. 4, pp. 469-478, 1993.
146 Santus G., and Baker. R.W., "Osmotic drug delivery: a review of the patent literature," J Controlled Release (1995) vol. 35 pp. 1-21.
147 Schaefer, T., et al., "Melt granulation in a laboratory scale high shear mixer," Drug Development and Industrial Pharmacy, vol. 16, No. 8, pp. 1249-1277 (1990).
148 Setiabidu R et al., "Dapsone N-Acetylation, Metoprolol, Alpha-Hydroxylation, and S-Mephenytoin 4-Hydroxylation Polymorphisms in an Indonesian Population: A Cocktail and Extended Phenotyping Assessment Trail," Clinical Pharmacology & Therapeutics, Mosby-Year Book, St Louis, MO, US, vol. 56, No. 2, Aug. 1994, pp. 142-153, XP008044975 ISSN: 0009-9236.
149 Shah et al., J. Cont. Rel. (1989) 9:169-175.
150 Siepmann et al., "A New Model Describing the Swelling and Drug Release Kinetics from Hydroxypropyl Methylcellulose Tablets", Journ. of Pharmaceutical Sciences, vol. 88, No. 1, pp. 65-72, Jan. 1999.
151 Summons to Attend Oral Proceedings issued in connection with European Patent Application No. 05019453.9 on Jul. 23, 2010.
152 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 01992565.0.
153 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10177508.8.
154 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179086.3.
155 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179087.1.
156 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10180984.6.
157 Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10181032.3.
158 Sung et al., "Effect of Formulation Variables on Drug and Polymer Release from HPMC-Based Matrix Tablets", International Journ. of Pharmaceutics vol. 142, pp. 53-60, 1996.
159 Sustained Release Medications, Noyes Data Corp., pp. 3,4, 10-15, 96-99, 335-337 (1980).
160 T. Hunt and R. Kaiko, "Comparison of the Pharmacokinetic Profiles of Two Oral Controlled-Release Morphine Formulation in Healthy Young Adults," Clin. Thera., vol. 13, No. 4, pp. 482-488, 1991.
161 The Merck Index, eleventh edition, pp. 757 and 1100 (1989).
162 Thomsen, L. Juul, "Prolonged Release Matrix Pellets prepared by Melt Pelletization II. Hydrophobic Substances as Meltable Binders," vol. 20, No. 77, pp. 1179-1197 (1994).
163 Thomsen, L. Juul, "Prolonged Release Matrix Pellets Prepared by Melt Pelletization. Part IV: Drug Particles Size, and Binder Composition," Pharmaceutical Technology Europa, pp. 19-24 (Oct. 1994).
164 Thomsen, L. Juul, "Utilizing melt pelletization technique for the preparation of prolonged release products," Pelletization, (material elaborated by assistant prof. Lars Jull Thomsen, Department of Pharmaceutics, Royal Danish School of Pharmacy of the Die course "Pelletization Technology," Nov. 1992, 106 pp. plus 3 appendices.
165 Thomsen, L. Juul, et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization I. Process Variables," Drug Development and Industrial Pharmacy, vol. 19, No. 15, pp. 1867-1887 (1993).
166 Toner G, Cramond T, Bishop, et al., "Randomized double blind, phase III crossover study of a new sustained-release oral mophine fornulation, Kapanol™ capsules," (Abstract 1001) International Association for the Study on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
167 Trandemate ER® Prescribing Information 2005.
168 Vashi et al., "Clinical Pharmacology and Pharmacokinetics of Once-Daily Hydromorphone Hydrochloride Extended-Release Capsules", J. Clin. Pharmacal, vol. 45, pp. 547-554, 2005.
169 Viriden et al., "Investigation of Critical Polymer Properties for Polymer Release and Swelling of HPMC Matrix Tablets", EP Journal of Pharmaceutical Sciences 36, pp. 297-309, 2009.
170 Webster, PTI-821: Sustained-Release Oxycodon Investig. Drugs, vol. 16, (3), pp. 1-8, 2007.
171 West R. J., et al., "Single dose pharmacokinetics of a new oral sustained release morphine formulation, Kapanol™ capsules," (Abstract 997) International Association for the Study of Pain, 7th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding).
172 Wiktionary, "dispersed," p. 1, http://en.wiktionary.org/wiki/disperse retrived on Apr. 30, 2006.
173 Yokokawa N., et al., "Relationship between plasma concentration of morphine and analgesic effectiveness," Postgrad Med J. (1991) 67 (Suppl. 2) pp. S50-S54.
174 Zimm et al., Pharmaceutical Development and Technology, 1(1), 37-42 (1996) "Drug Release from a Multiparticulate Pallet System."
175 Zohydro ER Hydrocodone Bitartrate Extended-Release (HC-ER) Dec. 7, 2012.
176 Zohydro ER Package Insert revised Oct. 2013.
US9060940 * 14 Mar 2014 23 Jun 2015 Purdue Pharma L.P. Controlled release hydrocodone
Clasificación internacional A61K9/00, A61K9/48, A61K9/54, A61K9/20, A61K9/22, A61P25/04, A61K9/24, A61K9/26, A61K31/485, C07D489/02, A61K9/52, A61K31/194